Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSIST COPD-2: Efficacy and Safety of Felcorekibart in COPD
NCT07780656Phase 3Recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 3 trial of felcorekibart in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Sep 2026; status: recruiting.
02
Drugs
felcorekibart
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07780656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07780656.